Navigation Links
Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
Date:11/6/2008

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it will host a conference call and webcast on Thursday, November 13, 2008, at 4:30 pm EST to review the Company's third quarter 2008 financial results and provide an update on recent corporate developments.

To access the live call, dial 877-675-4756 (domestic) or 719-325-4902 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs,
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
2. Interleukin-12 indicates survival prospects for melanoma patients
3. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. T cell immunity enhanced by timing of interleukin-7 therapy
6. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
7. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
8. Penn scientists map molecular regulation of fat-cell genetics
9. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
10. Genetics, Environment Shape Sexual Behavior
11. Homosexual behavior due to genetics and environmental factors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...RNewswire/--TheBartleHallConventionCenterwilltempo...-10,whenKansasCityhoststhelatestinaseriesofmassive...iceventhasthepotentialtobethebiggestoneyet,because...weekdaysinsteadofoveraweekend,"SheriWood,executive...toftheNationalAssociationofFreeClinics(NAFC). ,...
(Date:11/25/2009)...re/-SentinelleMedicalInc.,aleadingmanufacturerofbr...esasuiteofnewleadingedgeclinicalapplicationsonitsA...RadiologicalSocietyofNorthAmerica(RSNA)annualmeeti...applicationsleveragetheuniquehighqualityimagesgene...pportmultipleimagingmodalitiesformulti-parametrica...
(Date:11/25/2009)...swire-USNewswire/--TheBlackAIDSInstituterecentlyhe...ershipfor2010. ,, ThenewBoardMembersareahighlyd...law,finance,governmenthealthprograms,editorial,and...erangeofpersonalbackgroundsincludingbothheterosexu...es,andrepresentingmultipleagegroups. ,, (Photo:...
(Date:11/25/2009)...ular cancer who were treated with cisplatin-based ...ng neurological side effects and Raynaud-like phen...rapy, according to a new study published online No...nstitute . , Marianne Brydy, M.D., of the Depart...n Bergen, Norway, and colleagues conducted a cross...
(Date:11/25/2009)...essure? This simple question has been the focus o...ated gene Modulates High Blood Pressure in Mice & ...imple question has been the focus of intense resea...first time established a link between a novel gene...ress in mice as well as humans. The studies were d...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
... at reducing problems in heart transplant patients...y the drug reduced the incidence of a serious diso...wn as coronary vasculopathy.// Previous studi... University in Philadelphia conducted a study to d...
...nerable to serious brain injuries when they fall t...tigators distinguish between accidental and intent...a study found that rotational forces generated by ...issue and alter brain function, and nerve cell dam...
...ly common procedure for hard-to-treat cancers. The...take months or even years for stem cells// to beco...is at risk for serious infection. Now, researchers...experimental treatment. In Ed Bauters case...
...t sperm as they get older //and they found to thei...perm an edge. The deformed sperm increase the r...less are likely to beat out their healthy counterp...e is more common in children born to older fathers...
...thma attacks be causing the very thing it aims to ... School of Public Health and Brigham and Women’s H...wn as beta-agonists in asthmatics. Beta-ago...pill or liquid form, delivered in a nebulizer, or ...
...ath rate from it is falling due to early detection...versity of Southern Denmark carried out an analysi...ween 1993 and 1999. While the proportion of pe...Commenting on the findings published in this week'...
Other Medicine News:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...ry-USMarketTrends&Analysis http://www.reportl...arket-Trends--Analysis.html ,, TheUSintranasal...uticapplicationsfromthedeliveryofconventionallocal...drugs.Thefutureofthetechnologyhingesontotheeffecti...
(Date:11/25/2009)...re/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII...ectiveRandomizedOralTherapyEvaluationinCrohn,sdise...moderate-to-severeCrohn,sdiseasedemonstratedclinic...le.Thestudydemonstratedevidenceofclinicalefficacyi...decreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpa...
(Date:11/24/2009)...stCall/--Endologix,Inc.(Nasdaq: ELGX ),developerof...uncedtodaythatithasfiledamotiontostay,ordiscontinu...ghtagainstitinOctober2009byCook,Inc.Themotionwasfi...diana. ,, Endologixhasrequestedthatthestayremai...ice(USPTO)conductsproceedingstore-examinethetwopat...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 1National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
...linical program to evaluate PROMUS(TM) Element(TM)...3 Boston Scientific Corporation (NYSE: BSX ) to...in the PLATINUM clinical trial, which is designed ...verolimus-Eluting Coronary Stent. The first U.S. ...er of the Rockies in Loveland, Colorado by Thomas ...
...NG-WEIHENSTEPHAN, Germany, February 3 Pieris AG, ...R), a novel class of targeted,human protein therap...,progress in the development of its Anticalin(R) c...oad therapeutic applicability. , Having succes...in vitro,and in vivo, Pieris has now validated the...
Other Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 2Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 3
Alkaline Phosphatase
Uric Acid (Uricase) (Single Reagent)
Uric acid FS TBHBA
Uric Acid
Medicine Products: